Cytokinetics plunges as tirasemtiv fails to BENEFIT-ALS
This article was originally published in Scrip
Executive Summary
Cytokinetics lost $303m worth of market value on 25 April after the company reported that its drug tirasemtiv caused a greater numerical loss of function for individuals with amyotrophic lateral sclerosis (ALS) than placebo in the 711-patient Phase IIb BENEFIT-ALS clinical trial.